Published in Neurology on February 01, 1998
Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: A beneficial antitumor immune response going awry. Oncoimmunology (2013) 0.99
Lack of association between human leukocyte antigens and anti-Hu syndrome in patients with small-cell lung cancer. Neurology (1999) 0.75
Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry (2004) 10.58
Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain (2001) 5.04
Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med (2000) 3.95
Fall detection--principles and methods. Conf Proc IEEE Eng Med Biol Soc (2007) 3.45
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet (2003) 3.23
Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) (1992) 3.21
CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. J Immunol (1996) 3.02
Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS (1998) 2.90
What is known about the prevention of congenital toxoplasmosis? Lancet (1990) 2.78
Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol (2010) 2.77
Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain (1997) 2.64
Radiation-induced dementia in patients cured of brain metastases. Neurology (1989) 2.59
Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med (1990) 2.54
Cerebrovascular complications in patients with cancer. Medicine (Baltimore) (1985) 2.39
Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain (2001) 2.34
Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol (2001) 2.24
Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology (2000) 2.17
Patterns of disclosure and perceptions of the human immunodeficiency virus in infected elementary school-age children. Arch Pediatr Adolesc Med (1997) 2.14
Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS (2000) 2.14
A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity (1994) 2.09
The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer (2005) 2.09
Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol (2003) 2.01
SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology (2007) 2.00
Analysis of relapses in anti-NMDAR encephalitis. Neurology (2011) 1.98
Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood (2001) 1.98
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol (2004) 1.97
Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol (1999) 1.91
Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol (2001) 1.90
Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology (1985) 1.86
Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity. Neurology (1997) 1.85
Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol (2010) 1.85
Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV Infection in Newborns French Collaborative Study Group. Am J Epidemiol (1995) 1.84
Motor neuron syndromes in cancer patients. Ann Neurol (1997) 1.82
Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology (2004) 1.81
Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. Am J Med (1986) 1.79
Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology (2003) 1.79
Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood (1996) 1.78
Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology (2004) 1.77
Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology (1996) 1.74
Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain (1997) 1.73
GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology (2011) 1.71
Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science (2000) 1.70
Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. Clin Infect Dis (2001) 1.68
Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol (2006) 1.67
Autoantibodies in paraneoplastic syndromes associated with small-cell lung cancer. Neurology (1988) 1.66
Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies. Eur J Neurol (2012) 1.62
Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry (2000) 1.59
Neurological complications of radiotherapy and chemotherapy. J Neurol (1998) 1.56
Cyclosporine-associated mutism in liver transplant patients. Neurology (1996) 1.49
Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology (2009) 1.48
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol (2001) 1.47
Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology (1992) 1.47
Brainstem gliomas in adults: prognostic factors and classification. Brain (2001) 1.46
Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen. Ann Neurol (1985) 1.46
Antigen-dependent and -independent Ca2+ responses triggered in T cells by dendritic cells compared with B cells. J Exp Med (1998) 1.46
Taenia solium disease in humans and pigs: an ancient parasitosis disease rooted in developing countries and emerging as a major health problem of global dimensions. Microbes Infect (2000) 1.45
Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study. J Neurooncol (1989) 1.45
Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology (2008) 1.44
Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective. Vox Sang (2001) 1.40
Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm (2000) 1.39
[Spinal cord compression in cancer patients]. Med Clin (Barc) (1997) 1.39
Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry (1996) 1.39
[Chronic meningitis before diagnosis of celiac disease]. Rev Neurol (Paris) (2002) 1.39
Changes in enteric neurone phenotype and intestinal functions in a transgenic mouse model of enteric glia disruption. Gut (2005) 1.39
Partial characterization of the Purkinje cell antigens in paraneoplastic cerebellar degeneration. Neurology (1986) 1.39
Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res (1999) 1.38
Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer (1995) 1.36
Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Blood (1999) 1.36
Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome. Medicine (Baltimore) (1988) 1.35
Neurological complications of primary Sjögren's syndrome. J Neurol (2001) 1.34
Initial chemotherapy in gliomatosis cerebri. Neurology (2004) 1.33
Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. HIV Med (2008) 1.29
Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology (2000) 1.28
Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res (2000) 1.27
Significance of highly positive c22-3 "indeterminate" second-generation hepatitis C virus (HCV) recombinant immunoblot assay (RIBA) and resolution by third-generation HCV RIBA. J Clin Microbiol (1994) 1.26
Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy. Neurology (1991) 1.26
Antigen-presenting cells in adoptively transferred and spontaneous autoimmune diabetes. Eur J Immunol (1993) 1.24
CD4+CD7-CD57+ T cells: a new T-lymphocyte subset expanded during human immunodeficiency virus infection. Blood (1992) 1.23
Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry (2008) 1.22
Central nervous system involvement in mantle cell lymphoma. Ann Oncol (2007) 1.22
Imaging antigen recognition by naive CD4+ T cells: compulsory cytoskeletal alterations for the triggering of an intracellular calcium response. Eur J Immunol (1998) 1.22
Record-linkage between two anonymous databases for a capture-recapture estimation of underreporting of AIDS cases: France 1990-1993. The Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodéficience Humaine. Int J Epidemiol (2000) 1.21
Indolent anti-Hu-associated paraneoplastic sensory neuropathy. Neurology (1994) 1.20
Spectrum of paraneoplastic disease associated with lymphoma. Neurology (2011) 1.20
OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet (2001) 1.19
Protein kinase Cgamma autoimmunity in paraneoplastic cerebellar degeneration and non-small-cell lung cancer. J Neurol Neurosurg Psychiatry (2006) 1.18
EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. Eur J Neurol (2006) 1.17